Uptake in the United States has been low, despite several authorised therapies and promising clinical trial results
In the early days of the pandemic, researchers raced to identify the most potent antibodies produced by the immune system in response to SAR-COV-2 infection and produce them in bulk. The resulting ‘monoclonal antibodies’ have since been tested in a variety of settings as treatments for COVID-19.
But despite promising clinical trial results and several therapies having already been approved, antibody therapies have not yet played a large role in the fight against COVID-19. In this episode of Coronapod, we ask why.
Source: Nature.com/authentic news

মন্তব্যসমূহ
একটি মন্তব্য পোস্ট করুন